Atlas Trials

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Clinical trial NCT03749018 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03749018
Sponsor
David Bond, MD
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Aggressive Non-Hodgkin LymphomaAnn Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage II B-Cell Non-Hodgkin LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaDiffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedIndolent Non-Hodgkin Lymphoma
Start date
2019-01-02
Primary completion
2026-02-02
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.